Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Marissa D. Friedman
Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis
Clinical Breast Cancer
Cancer Research
Oncology
Related publications
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-Negative HER2-Overexpressed Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Patient With Metastatic Breast Cancer, HER2-positive, Trastuzumab- And Pertuzumab-Resistant Responding to Lapatinib
AboutOpen
Trastuzumab Plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
New England Journal of Medicine
Medicine
A Randomized, Controlled Phase II Trial of Neoadjuvant Ado-Trastuzumab Emtansine, Lapatinib, and Nab-Paclitaxel Versus Trastuzumab, Pertuzumab, and Paclitaxel in HER2-positive Breast Cancer (TEAL Study)
Breast Cancer Research
Cancer Research
Oncology
An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer
Oncologist
Cancer Research
Medicine
Oncology
Pcn74 - A Budget-Impact Analysis of Adjuvant Pertuzumab and Trastuzumab in Early Her2-Positive Breast Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
Frontiers in Oncology
Cancer Research
Oncology
Trastuzumab in Combination With AT-101 Induces Cytotoxicity and Apoptosis in Her2 Positive Breast Cancer Cells
Future Oncology
Medicine
Cancer Research
Oncology
Cost-Utility Analysis of Adjuvant Trastuzumab Therapy for HER2-positive Early-Stage Breast Cancer in the Philippines
BMC Health Services Research
Health Policy
